Mirum Pharmaceuticals, Inc. (MIRM) Wins FDA Nod for Atebrioz in FOP

The FDA approved Atebrioz (zilurgisertib) tablets to reduce total new heterotopic ossification in FOP patients aged 12+, licensed by Incyte to Mirum. A Rare Pediatric Disease PRV was issued to Incyte.Material DetailsContext by AI AnalystThis is a late-stage regulatory milestone that converts a pipe…